HK1252799A1 - 封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途 - Google Patents

封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途

Info

Publication number: HK1252799A1
Authority: HK; Hong Kong
Prior art keywords: antibody; capped; uncapped; cysteines; drug conjugation
Prior art date: 2015-08-12

Application number

HK18112100.2A

Other languages

English (en)

Inventor

Xiaotian Zhong

Amarnauth Shastrie Prashad

Ronald William Kriz

Tao He

Will Somers

Wenge Wang

Leo Joseph Letendre

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-12

Filing date

2018-09-20

Publication date

2019-06-06

2018-09-20 Application filed by Pfizer filed Critical Pfizer

2019-06-06 Publication of HK1252799A1 publication Critical patent/HK1252799A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK18112100.2A 2015-08-12 2018-09-20 封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途 HK1252799A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562204005P	2015-08-12	2015-08-12

Publications (1)

Publication Number	Publication Date
HK1252799A1 true HK1252799A1 (zh)	2019-06-06

Family

ID=56855760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18112100.2A HK1252799A1 (zh)	2015-08-12	2018-09-20	封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途

Country Status (19)

Country	Link
US (2)	US10653794B2 (zh)
EP (2)	EP3334760B1 (zh)
JP (2)	JP6865209B2 (zh)
KR (2)	KR102146617B1 (zh)
CN (1)	CN107849121B (zh)
AU (1)	AU2016305331B2 (zh)
CA (1)	CA2938333A1 (zh)
DK (1)	DK3334760T3 (zh)
ES (1)	ES2864842T3 (zh)
HK (1)	HK1252799A1 (zh)
HR (1)	HRP20210579T1 (zh)
HU (1)	HUE053956T2 (zh)
IL (1)	IL257420B (zh)
MX (1)	MX2018001686A (zh)
PL (1)	PL3334760T3 (zh)
PT (1)	PT3334760T (zh)
RU (2)	RU2742260C2 (zh)
SI (1)	SI3334760T1 (zh)
WO (1)	WO2017025897A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2742260C2 (ru) *	2015-08-12	2021-02-04	Пфайзер Инк.	Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство
KR102322530B1 (ko) *	2017-02-08	2021-11-05	화이자 인코포레이티드	캡핑된 및 비-캡핑된 항체 시스테인의 대규모 제조 공정 및 치료 단백질 접합에서의 그의 용도
LT3661562T (lt) *	2017-08-04	2024-10-25	Amgen Inc.	Cys-mab konjugavimo būdas
WO2020164561A1 (en)	2019-02-15	2020-08-20	Wuxi Biologics (Shanghai) Co. Ltd.	Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en)	2019-02-15	2024-10-08	Wuxi Xdc Singapore Private Limited	Process for preparing antibody-drug conjugates with improved homogeneity
CA3205650A1 (en) *	2020-12-22	2022-06-30	Novartis Ag	Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
WO2023067626A1 (en) *	2021-10-20	2023-04-27	Dr. Reddy's Laboratories Limited	A cell culture process to produce an antibody composition
WO2025038435A1 (en) *	2023-08-11	2025-02-20	Amgen Inc.	Methods of solid phase antibody conjugation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5241078A (en) *	1988-06-14	1993-08-31	Cetus Oncology	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
JP3951062B2 (ja) *	1991-09-19	2007-08-01	ジェネンテック・インコーポレーテッド	少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
IL144259A0 (en) *	1999-01-14	2002-05-23	Bolder Biotechnology Inc	Methods for making proteins containing free cysteine residues
CA2468971A1 (en) *	2001-12-04	2003-06-12	Mitsubishi Pharma Corporation	Method of activating protein
WO2006134173A2 (en) *	2005-06-17	2006-12-21	Novo Nordisk Health Care Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
KR20090016727A (ko) *	2006-05-26	2009-02-17	소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스.	부위 특이적 페길화 방법
WO2009009523A2 (en) *	2007-07-09	2009-01-15	Genentech, Inc.	Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2009205995B2 (en) *	2008-01-18	2014-04-03	Medimmune, Llc	Cysteine engineered antibodies for site-specific conjugation
US8623598B2 (en) *	2008-03-19	2014-01-07	Intelligent Bio Systems, Inc.	Methods and compositions for inhibiting undesired cleaving of labels
EP2448966B1 (en)	2009-07-03	2018-11-14	Avipep Pty Ltd	Immuno-conjugates and methods for producing them
US9005926B2 (en) *	2009-10-02	2015-04-14	Biogen Idec Ma Inc.	Methods of preventing and removing trisulfide bonds
WO2011069104A2 (en) *	2009-12-04	2011-06-09	Genentech, Inc.	Multispecific antibodies, antibody analogs, compositions, and methods
MX336540B (es) *	2010-06-08	2016-01-22	Genentech Inc	Conjugados y anticuerpos manipulados geneticamente con cisteina.
US20120301429A1 (en) *	2011-05-27	2012-11-29	Hartman Taymar E	Dac hyp compositions and methods
KR101541764B1 (ko) *	2012-02-24	2015-08-05	(주)알테오젠	시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법
US9018172B2 (en)	2012-09-26	2015-04-28	Massachusetts Institute Of Technology	Modification of peptides via SNAr reactions of thiols with fluorinated aromatics
BR112016010051A2 (pt) *	2013-11-04	2017-12-05	Pfizer	?conjugados de anticorpo-fármaco anti-efna4?
WO2015085003A1 (en) *	2013-12-04	2015-06-11	Immunogen, Inc.	Compositions and methods for antibody production
WO2015110935A1 (en)	2014-01-27	2015-07-30	Pfizer Inc.	Bifunctional cytotoxic agents
SG11201706991YA (en)	2015-03-20	2017-10-30	Pfizer	Bifunctional cytotoxic agents containing the cti pharmacophore
RU2742260C2 (ru) *	2015-08-12	2021-02-04	Пфайзер Инк.	Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство

2016
- 2016-08-09 RU RU2018105128A patent/RU2742260C2/ru active
- 2016-08-09 ES ES16760548T patent/ES2864842T3/es active Active
- 2016-08-09 IL IL257420A patent/IL257420B/en unknown
- 2016-08-09 EP EP16760548.4A patent/EP3334760B1/en active Active
- 2016-08-09 KR KR1020187006927A patent/KR102146617B1/ko active Active
- 2016-08-09 HU HUE16760548A patent/HUE053956T2/hu unknown
- 2016-08-09 EP EP20207006.6A patent/EP3808768A1/en active Pending
- 2016-08-09 SI SI201631163T patent/SI3334760T1/sl unknown
- 2016-08-09 PL PL16760548T patent/PL3334760T3/pl unknown
- 2016-08-09 US US15/748,268 patent/US10653794B2/en active Active
- 2016-08-09 DK DK16760548.4T patent/DK3334760T3/da active
- 2016-08-09 KR KR1020207023230A patent/KR102319622B1/ko active Active
- 2016-08-09 MX MX2018001686A patent/MX2018001686A/es unknown
- 2016-08-09 JP JP2018506438A patent/JP6865209B2/ja active Active
- 2016-08-09 RU RU2021101009A patent/RU2021101009A/ru unknown
- 2016-08-09 PT PT167605484T patent/PT3334760T/pt unknown
- 2016-08-09 CA CA2938333A patent/CA2938333A1/en active Pending
- 2016-08-09 AU AU2016305331A patent/AU2016305331B2/en active Active
- 2016-08-09 CN CN201680047377.XA patent/CN107849121B/zh active Active
- 2016-08-09 WO PCT/IB2016/054789 patent/WO2017025897A2/en active Application Filing
2018
- 2018-09-20 HK HK18112100.2A patent/HK1252799A1/zh unknown
2020
- 2020-03-03 US US16/807,375 patent/US11980669B2/en active Active
2021
- 2021-04-05 JP JP2021063975A patent/JP2021118694A/ja active Pending
- 2021-04-12 HR HRP20210579TT patent/HRP20210579T1/hr unknown

Also Published As

Publication number	Publication date
KR102319622B1 (ko)	2021-11-02
CN107849121A (zh)	2018-03-27
KR20200100850A (ko)	2020-08-26
RU2018105128A (ru)	2019-09-12
PT3334760T (pt)	2021-04-23
SI3334760T1 (sl)	2021-07-30
RU2021101009A (ru)	2021-02-20
MX2018001686A (es)	2019-01-31
ES2864842T3 (es)	2021-10-14
JP2021118694A (ja)	2021-08-12
IL257420B (en)	2022-08-01
EP3808768A1 (en)	2021-04-21
KR102146617B1 (ko)	2020-08-20
HUE053956T2 (hu)	2021-08-30
IL257420A (en)	2018-06-28
DK3334760T3 (da)	2021-04-19
CA2938333A1 (en)	2017-02-12
US20200230256A1 (en)	2020-07-23
BR112018001904A2 (pt)	2018-09-18
AU2016305331B2 (en)	2019-05-16
JP2018525990A (ja)	2018-09-13
WO2017025897A2 (en)	2017-02-16
CN107849121B (zh)	2021-11-09
US11980669B2 (en)	2024-05-14
RU2742260C2 (ru)	2021-02-04
KR20180038041A (ko)	2018-04-13
RU2018105128A3 (zh)	2020-07-27
US10653794B2 (en)	2020-05-19
US20190030183A1 (en)	2019-01-31
PL3334760T3 (pl)	2021-10-11
EP3334760A2 (en)	2018-06-20
AU2016305331A1 (en)	2018-02-15
JP6865209B2 (ja)	2021-04-28
WO2017025897A3 (en)	2017-04-06
EP3334760B1 (en)	2021-03-10
HRP20210579T1 (hr)	2021-05-28

Publication	Publication Date	Title
HK1252799A1 (zh)	2019-06-06	封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途
IL267323A (en)	2019-08-29	Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
IL247248A0 (en)	2016-09-29	Anti-dll3 antibodies and drug conjugates for use in melanoma
PL3378859T3 (pl)	2020-04-30	Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynie
IL248239A0 (en)	2016-11-30	Drug conjugates - antibody against - her3, preparations containing them and their uses
HUE053332T2 (hu)	2021-06-28	Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
IL245252B (en)	2019-06-30	Anti-her2 drug-antibody conjugates, preparations containing them and their uses
IL247659A0 (en)	2016-11-30	Antibodies against immunogenic glycopeptides, a preparation containing them and their use
HUE054037T2 (hu)	2021-08-30	CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
GB2562059B (en)	2020-08-12	Improvements in and relating to barriers
SI3265123T1 (sl)	2023-02-28	Protitelesa, uporabe in postopki
HK1254864A1 (zh)	2019-07-26	Hbed-二膦酸鹽/酯、其放射金屬軛合物和它們作為治療診斷劑的用途
GB201717966D0 (en)	2017-12-13	Immunotoxins, formulations thereof and their use in medicine
IL266112A (en)	2019-06-30	Antibodies against edb and antibody-drug conjugates
HUE052751T2 (hu)	2021-05-28	Natív OMV-antigén konjugátumok és alkalmazásuk
GB201614162D0 (en)	2016-10-05	Antibodies, uses thereof and conjugates thereof
IL249453A0 (en)	2017-02-28	Texapyrin conjugates and preparations - pt(iv) for use in overcoming resistance to platinum
ZA201706254B (en)	2018-12-19	Oil blends, processes for the preparation thereof and their use in formulas
GB201419108D0 (en)	2014-12-10	Materials and methods relating to linkers for use in antibody drug conjugates
RS56132B1 (sr)	2017-10-31	Grupa za lepljenje sa uređajem za podesivi pristup kod laminator-utiskivača, odnosni laminator-utiskivač i postupak za podešavanje pristupa
IL237283A0 (en)	2015-07-30	Dldh and its derivatives, and preparations containing them for medical use
GB2513859B (en)	2018-01-17	Agrochemical composition, method for its preparation and the use thereof
METROPOLIS	2014	THE SOCIAL AND THE NATIONAL QUESTION IN THE EASTERN METROPOLIS
GB201712096D0 (en)	2017-09-13	Immunogenic conjugates and use thereof
GB201609866D0 (en)	2016-07-20	Antibodies, uses thereof and conjugates thereof